Compare prices and buy PNC-27 from 2 research peptide vendors - also called suppliers or sources. Updated daily.
A 32-residue chimeric peptide fusing residues 12-26 of the p53 HDM-2-binding domain with a C-terminal membrane-penetrating sequence. Preclinically studied to selectively lyse cancer cells that expose HDM-2 on their plasma membrane, sparing normal cells. Research-only and not FDA-approved.
For research purposes only. Not medical advice.
PNC-27 is a laboratory construct rather than a peptide that occurs in nature, and everything published about it is cell-culture or animal work. It has no FDA approval, and PeptideScouter catalogues it under Experimental.
Kanovsky and colleagues introduced it in the Proceedings of the National Academy of Sciences in 2001, from the laboratories of Matthew Pincus and Josef Michl. That paper synthesized three peptides from the mdm-2-binding domain of human p53 and attached each, at its carboxyl terminus, to a 17-residue leader it calls the penetratin sequence and attributes to the antennapedia protein. PNC-27 carries p53 residues 12-26, the 15-residue stretch the paper identifies as the region contacting mdm-2. Fifteen plus seventeen gives the 32 residues vendor listings describe, and the 2010 paper below prints the full sequence.
The leader sits at that end because the paper's helix-probability calculations showed it raising the helical probability of exactly the residues the published crystal structure shows in contact with mdm-2.
The paper's images, stem-cell colony table and dose series were run with the shorter sibling PNC-28, and the text states that identical results were obtained with PNC-27 rather than showing them.
A second PNAS paper, Sarafraz-Yazdi and colleagues in 2010, proposed why the selectivity might exist. Membrane fractions from four cancer cell lines carried HDM-2 at four to nine times the share seen in three untransformed lines, and confocal microscopy placed the peptide and HDM-2 together in the membranes of treated cancer cells but not of untransformed ones.
The test of that model was a transfection. Untransformed human breast epithelial cells, which the peptide does not kill, were given full-length HDM-2 carrying a membrane-localization tag and became susceptible, releasing more than twice the background level of lactate dehydrogenase. Cells given the same construct with residues 1-109 deleted, the stretch that binds p53, did not, and no caspase activity rose above background in any group. The authors concluded that the peptide binds HDM-2 in the membrane, is held there instead of passing into the cell, and forms pores.
PNC-28 is p53 residues 17-26 joined to the same leader, and PNC-21 is residues 12-20. Anyone tracing the animal literature has to check which peptide a study used, because the 2006 pancreatic work in the International Journal of Cancer was PNC-28.
Animal work with PNC-27 itself appears in Leukemia in 2020, from Wang and colleagues at City of Hope, in two acute myeloid leukemia mouse models. Median survival was 54 days in treated animals against 41 for a control-peptide group and 42 for vehicle, and 136.5 against 115 and 111 days in mice carrying grafts of patient cells. The paper states that Oncolyze, Inc. supplied the peptide.
PeptideScouter found no US regulatory record for PNC-27. As of October 22, 2026, it appears in none of these:
They are different peptides from the same 2001 design series and the results are not interchangeable. PNC-27 carries residues 12-26 of the p53 mdm-2-binding domain, PNC-28 carries residues 17-26, and PNC-21 carries residues 12-20, each joined at its carboxyl terminus to the same 17-residue penetratin leader. PNC-28 also carries most of the published animal record, including the 2006 pancreatic-tumor study in the International Journal of Cancer, so an animal result quoted for PNC-27 is worth checking against the paper it came from.
The published papers describe necrosis rather than apoptosis. In the 2001 Proceedings of the National Academy of Sciences report, DNA from treated transformed cells in culture broke into progressively lower-molecular-weight fragments, the opposite of the higher-molecular-weight laddering the same group obtained by irradiating cells or treating them with actinomycin D, and the apoptosis-associated proteins Bax, wafp21, p53, c-myc and bcl-2 were not detectable. A 2010 follow-up in the same journal found no rise in caspase activity and attributed the cell death to pore formation in the membrane. All of this is cell-culture evidence.
Yes, in mice. The clearest example using PNC-27 itself rather than a sibling peptide is a 2020 paper in Leukemia from a City of Hope group, which treated two acute myeloid leukemia mouse models. Median survival was 54 days in treated animals against 41 days for a control-peptide group and 42 days for vehicle in the murine model, and 136.5 against 115 and 111 days in mice carrying grafts of patient cells.
None that PeptideScouter could find, as of October 22, 2026. The compound is absent from FDA's Drugs@FDA database, from both tables of the Category 2 bulk-substance list, from the substances nominated for compounding under Sections 503A and 503B, from the substances FDA named for its July 2026 Pharmacy Compounding Advisory Committee meeting and for its next one, due before the end of February 2027, from FDA's GSRS substance registry searched by name and by sequence, and from FDA's warning-letter database. ClinicalTrials.gov returns no study for it either by name or as an intervention, so no human trial is registered.
From a cell-penetrating sequence, not from p53. The 2001 paper that introduced the construct describes a 17-residue leader that it calls the penetratin sequence and attributes to the antennapedia protein, and it put that leader at the carboxyl end because its own helix-probability calculations showed that position stabilized the helix in the p53 residues that contact mdm-2. A 2010 paper from the same group calls the same stretch a transmembrane-penetrating or membrane-residency sequence.
PNC-27 is sold by 2 research peptide vendors indexed on PeptideScouter, with 2 tracked listings compared per vendor in the table above. Pricing is normalized and refreshed daily.
1 of the 2 indexed vendors currently have PNC-27 in stock. The comparison table marks out-of-stock listings, and stock state is refreshed daily.
PSPeptides currently lists PNC-27 at $11.00/mg, the lowest listed price across 2 tracked research peptide vendors. With current vendor discount codes applied, the lowest effective price is $9.90/mg.
Discount codes are issued per vendor rather than per peptide, so any code applies across that vendor's whole catalog. All 2 vendors listing PNC-27 publish a PeptideScouter code, worth 10% to 15% off. Applied, the lowest effective price falls from $11.00/mg listed to $9.90/mg at PSPeptides. Each vendor's code is shown beside its price in the table above.
PNC-27 ranges from $11.00/mg to $11.90/mg across 2 listings from 2 research peptide vendors, normalized to USD per milligram and refreshed daily.
2 research peptide vendors currently list PNC-27 on PeptideScouter, with 1 in stock right now. We track 2 listings across size and kit variants.
PNC-27's CAS Registry Number is 1159861-00-3.
